cromolyn sodium has been researched along with iproniazid in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Gruetter, CA; Lemke, SM; Szarek, JL; Valentovic, MA | 1 |
2 other study(ies) available for cromolyn sodium and iproniazid
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Evidence that histamine is involved as a mediator of endothelium-dependent contraction induced by A23187 in bovine intrapulmonary vein.
Topics: Animals; Arginine; Atropine; Calcimycin; Cattle; Cromolyn Sodium; Endothelins; Endothelium, Vascular; Hemoglobins; Histamine; Histamine H1 Antagonists; Histamine Release; In Vitro Techniques; Iproniazid; Methylene Blue; Muscle Contraction; Muscle, Smooth, Vascular; omega-N-Methylarginine; p-Methoxy-N-methylphenethylamine; Pulmonary Veins; Thioxanthenes; Xanthones | 1994 |